Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets
CompanyDeals

Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets

RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai’ai and Disitamab Vedotin
Company

RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai’ai and Disitamab Vedotin

Eli Lilly’s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial
CompanyDrug

Eli Lilly’s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial

Company

Hansoh Pharma Reports 22.6% Revenue Growth in 2025, Driven by Oncology and $4.54B in Global Licensing Deals

Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M
Company

Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M

Eli Lilly’s Lebrikizumab Demonstrates Four-Year Sustained Efficacy in Atopic Dermatitis, Reinforcing IL-13 as Core Therapeutic Target
CompanyDrug

Eli Lilly’s Lebrikizumab Demonstrates Four-Year Sustained Efficacy in Atopic Dermatitis, Reinforcing IL-13 as Core Therapeutic Target

CompanyDeals

BrainAurora Medical Partners with Tokyo Lifestyle to Launch AI-Powered Digital Health Platform for Elderly Cognitive Care Across Asia

UCB's Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa
CompanyDrug

UCB’s Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa

Enhertu Wins China Approval for HER2+ Early Breast Cancer – ADC Sequential Therapy Shows 67% pCR Rate in Phase III DESTINY-Breast11
CompanyDrug

Enhertu Wins China Approval for HER2+ Early Breast Cancer – ADC Sequential Therapy Shows 67% pCR Rate in Phase III DESTINY-Breast11

CompanyDrug

FDA Approves Rocket Pharma’s Kresladi – First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

CompanyDeals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Novo Nordisk's Awiqli Wins FDA Approval – World's First Once-Weekly Basal Insulin for Type 2 Diabetes
CompanyDrug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes